Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 22 December 2017 Roche and Ignyta reach definitive merger agreement more Published on: 21 December 2017 FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer more Published on: 21 December 2017 European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer more Published on: 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia more Published on: 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer more Published on: 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma more Published on: 9 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors more Published on: 7 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A more Published on: 7 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer more Published on: 4 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics more Published on: 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A more Published on: 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer more Published on: 17 November 2017 Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain more Published on: 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma more Published on: 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors more Published on: 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis more Published on: 7 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation more Published on: 7 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer more Published on: 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting more Published on: 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis more Published on: 24 October 2017 Roche recognised as a global leader for sustainable water management more Published on: 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 more Published on: 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS more Published on: 13 October 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC more Published on: 6 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus more Published on: 3 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams more Published on: 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer more Published on: 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis more Published on: 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer more Published on: 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma more Published on: 22 September 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis more Published on: 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan more Published on: 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS more Published on: 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma more Published on: 8 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration more Published on: 8 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress more Published on: 7 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices more Published on: 6 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer more Published on: 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress more Published on: 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome more Published on: 24 August 2017 FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors more Published on: 27 July 2017 Roche reports strong performance in the first half of 2017 more Published on: 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis more Published on: 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma more Published on: 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer more Published on: 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia more Published on: 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine more Published on: 3 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections more Published on: 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management more Published on: 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) more Published on: 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors more Published on: 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers more Published on: 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma more Published on: 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers more Published on: 23 June 2017 New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis more Published on: 14 June 2017 Roche’s employee-driven philanthropic campaign sets new record more Published on: 5 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer more Published on: 5 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer more Published on: 3 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 more Published on: 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) more Published on: 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis more Published on: 11 May 2017 Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer more Published on: 8 May 2017 Roche launches AVENIO ctDNA Analysis Kits for Oncology Research more Published on: 27 April 2017 Roche reports a good start in 2017 more Published on: 26 April 2017 New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis more Published on: 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis more Published on: 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States more Published on: 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer more Published on: 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A more Published on: 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer more Published on: 5 April 2017 Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance more Published on: 3 April 2017 Roche launches cobas Liat PCR System with four assays into CE-markets more Published on: 3 April 2017 Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer more Published on: 29 March 2017 FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis more Published on: 28 March 2017 Roche announces launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets accepting the CE mark more Published on: 14 March 2017 Roche Annual General Meeting 2017 more Published on: 2 March 2017 Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy more Published on: 21 February 2017 Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer more Published on: 18 February 2017 Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma more Published on: 1 February 2017 Roche reports good results in 2016 more Published on: 23 January 2017 Roche enters a new era in haematology testing, with the launch of the new cobas m 511 analyser more Published on: 9 January 2017 FDA grants Roche’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer more
Published on: 21 December 2017 FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer more
Published on: 21 December 2017 European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer more
Published on: 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia more
Published on: 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer more
Published on: 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma more
Published on: 9 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors more
Published on: 7 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A more
Published on: 7 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer more
Published on: 4 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics more
Published on: 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A more
Published on: 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer more
Published on: 17 November 2017 Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain more
Published on: 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma more
Published on: 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors more
Published on: 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis more
Published on: 7 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation more
Published on: 7 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer more
Published on: 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting more
Published on: 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis more
Published on: 24 October 2017 Roche recognised as a global leader for sustainable water management more
Published on: 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 more
Published on: 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS more
Published on: 13 October 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC more
Published on: 6 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus more
Published on: 3 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams more
Published on: 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer more
Published on: 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis more
Published on: 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer more
Published on: 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma more
Published on: 22 September 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis more
Published on: 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan more
Published on: 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS more
Published on: 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma more
Published on: 8 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration more
Published on: 8 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress more
Published on: 7 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices more
Published on: 6 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer more
Published on: 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress more
Published on: 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome more
Published on: 24 August 2017 FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors more
Published on: 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis more
Published on: 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma more
Published on: 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer more
Published on: 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia more
Published on: 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine more
Published on: 3 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections more
Published on: 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management more
Published on: 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) more
Published on: 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors more
Published on: 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers more
Published on: 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma more
Published on: 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers more
Published on: 23 June 2017 New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis more
Published on: 5 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer more
Published on: 5 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer more
Published on: 3 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 more
Published on: 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) more
Published on: 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis more
Published on: 11 May 2017 Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer more
Published on: 26 April 2017 New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis more
Published on: 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis more
Published on: 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States more
Published on: 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer more
Published on: 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A more
Published on: 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer more
Published on: 5 April 2017 Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance more
Published on: 3 April 2017 Roche launches cobas Liat PCR System with four assays into CE-markets more
Published on: 3 April 2017 Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer more
Published on: 29 March 2017 FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis more
Published on: 28 March 2017 Roche announces launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets accepting the CE mark more
Published on: 2 March 2017 Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy more
Published on: 21 February 2017 Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer more
Published on: 18 February 2017 Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma more
Published on: 23 January 2017 Roche enters a new era in haematology testing, with the launch of the new cobas m 511 analyser more
Published on: 9 January 2017 FDA grants Roche’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer more